Preprocedural Ticagrelor Treatment was Associated with Improved Early Reperfusion and Reduced Short-term Heart Failure in East-Asian ST-segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention

References

• Roffi M, Patrono C, Collet J-P, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267–315. doi:10.1093/eurheartj/ehv320
   PubMed Web of Science ®Google Scholar
• O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013;61(4):485–510. doi:10.1016/j.jacc.2012.11.018
   PubMed Web of Science ®Google Scholar
• Fröbert O, Lagerqvist B, Olivecrona GK. Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med. 2013;369(17):1587–1597. doi:10.1056/NEJMoa1308789
   PubMed Web of Science ®Google Scholar
• Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–177. doi:10.1093/eurheartj/ehx393
   PubMed Web of Science ®Google Scholar
• Montalescot G, Borentain M, Payot L, et al. Early vs. late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. JAMA. 2004;292(3):362–366. doi:10.1001/jama.292.3.362
   PubMed Web of Science ®Google Scholar
• De Luca G, Gibson CM, Bellandi F, et al. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis. Heart. 2008;94(12):1548–1558. doi:10.1136/hrt.2008.141648
   PubMed Web of Science ®Google Scholar
• Yong H, Lee SWL, Sawhney JPS. Contemporary pre-hospital management of acute coronary syndromes patients: results from the EPICOR Asia Study. Circulation. 2013;128:A14546.
   Web of Science ®Google Scholar
• Montalescot G, Van’t Hof AW, Lapostolle F, et al. Prehospital ticagrelor in ST segment elevation myocardial infarction. N Engl J Med. 2014;371(11):1016–1027. doi:10.1056/NEJMoa1407024
   PubMed Web of Science ®Google Scholar
• Sasha Koul J, Smith G, Götberg M, et al. No benefit of ticagrelor pretreatment compared with treatment during percutaneous coronary intervention in patients with ST-segment–elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circ Cardiovasc Interv. 2018;11(3):e005528.
   PubMed Web of Science ®Google Scholar
• Levine GN, Jeong Y-H, Goto S, et al. Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nat Rev Cardiol. 2014;11(10):597–606. doi:10.1038/nrcardio.2014.104
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Moulias A, Kanakakis I, Xanthopoulou I. Pre-hospital ticagrelor in ST-segment elevation myocardial infarction: ready for prime time? Int J Cardiol. 2015;194:41–43. doi:10.1016/j.ijcard.2015.05.064
   PubMed Web of Science ®Google Scholar
• Parodi G, Bellandi B, Xanthopoulou I, et al. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ Cardiovasc Interv. 2015;8(1):1–6. doi:10.1161/CIRCINTERVENTIONS.114.001593
   Web of Science ®Google Scholar
• Parodi G, Bellandi B, Xanthopoulou I, et al. Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2014;63(7):630–635. doi:10.1016/j.jacc.2013.10.068
   PubMed Web of Science ®Google Scholar
• Meine TJ, Roe MT, Chen AY, et al. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE quality improvement initiative. Am Heart J. 2005;149(6):1043–1049. doi:10.1016/j.ahj.2005.02.010
   PubMed Web of Science ®Google Scholar
• Parodi G, Valenti R, Bellandi B, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (rapid activity of platelet inhibitor drugs) primary PCI study. J Am Coll Cardiol. 2013;61(15):1601–1606. doi:10.1016/j.jacc.2013.01.024
   PubMed Web of Science ®Google Scholar
• Khan JN, Greenwood JP, Nazir SA, et al. Infarct size following treatment with second- versus third-generation P2Y12 antagonists in patients with multivessel coronary disease at ST-segment elevation myocardial infarction in the CvLPRIT Study. J Am Heart Assoc. 2016;5(6):e003403. doi:10.1161/JAHA.116.003403
   PubMed Web of Science ®Google Scholar
• Barletta KE, Ley K, Mehrad B. Regulation of neutrophil function by adenosine. Arterioscler Thromb Vasc Biol. 2012;32(4):856–864. doi:10.1161/ATVBAHA.111.226845
   PubMed Web of Science ®Google Scholar
• Csóka B, Németh ZH, Rosenberger P, et al. A2B adenosine receptors protect against sepsis-induced mortality by dampening excessive inflammation. J Immunol. 2010;185(1):542–550. doi:10.4049/jimmunol.0901295
   PubMed Web of Science ®Google Scholar
• Montalescot G, Van’t Hof AW, Bolognese L, et al. Effect of pre-hospital ticagrelor during the first 24h after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction: the ATLANTIC-H 24 analysis. JACC Cardiovasc Interv. 2016;9(7):646–656. doi:10.1016/j.jcin.2015.12.024
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Xanthopoulou I, Gkizas V, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv. 2012;5(6):797–804. doi:10.1161/CIRCINTERVENTIONS.112.972323
   PubMed Web of Science ®Google Scholar
• Cayla G, Lapostolle F, Ecollan P, et al. Pre-hospital ticagrelor in ST-segment elevation myocardial infarction in the French ATLANTIC population. Int J Cardiol. 2017;244:49–53. doi:10.1016/j.ijcard.2017.06.009
   PubMed Web of Science ®Google Scholar
• Morimoto T, Fukui T, Lee TH, Matsui K. Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan. Am J Med. 2004;117(7):459–468. doi:10.1016/j.amjmed.2004.04.017
   PubMed Web of Science ®Google Scholar
• Kwon TJ, Tantry US, Park Y, et al. Influence of platelet reactivity on BARC classification in East Asian patients undergoing percutaneous coronary intervention. Results of the ACCEL-BLEED Study. Thromb Haemost. 2016;115(5):979–992. doi:10.1160/TH15-05-0366
   PubMed Web of Science ®Google Scholar
• Small DS, Payne CD, Kothare P, et al. Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial. Clin Ther. 2010;32(2):365–379. doi:10.1016/j.clinthera.2010.02.015
   PubMed Web of Science ®Google Scholar